证券代码：000915 证券简称：华特达因 公告编号：2025-017 山东华特达因健康股份有限公司 关于拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 本次拟续聘会计师事务所符合财政部、国务院国资委、证监会印发的 《国有企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号） 的规定。 （三）诚信记录 致同所近三年因执业行为受到刑事处罚 0 次、行政处罚 2 次、监督管理 措施 15 次、自律监管措施 9 次和纪律处分 0 次。58 名从业人员近三年因 执业行为受到刑事处罚 0 次、行政处罚 11 次、监督管理措施 16 次、自律 监管措施 8 次和纪律处分 1 次。 二、项目信息 （一）人员信息 刘健，2007 年成为注册会计师，1998 年开始从事上市公司审计，2019 年开始在本所执业；近三年签署上市公司审计报告 8 份、签署新三板挂牌 公司审计报告 1 份。复核新三板挂牌公司 1 份。 山东华特达因健康股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开第十一届董事会第三次会议，审议通 ...

Group 1: Report Overview - Reported industry: Chemical Pharmaceuticals [2] - Research object: Watertime [17] - Reception time: April 16, 2025 [17] - Listed company reception staff: President Yang Jie, Independent Director Du Ning, Financial Controller Tan Lifu, Board Secretary Fan Liming [17] Group 2: Core Views - The company's cooperation with China Resources Sanjiu on Vitamin D Drops (capsule type) allows for complementary advantages and resource sharing, promoting the popularization of vitamin D supplements [24][44] - In 2024 Q3, the company's performance decline was due to factors such as the slowdown in the pharmaceutical industry, inactive market terminal sales, and intensified pharmacy competition. The company responded by increasing marketing efforts and optimizing strategies [25][45] - The company is promoting the bankruptcy of Watertime Information, the dissolution and liquidation of Watertime Zhixin, and addressing the asset occupation issue of Yinan Watertime Wolong School [26] - The company aims to form multi - category flagship products, optimize channel layout, and build an honest, capable, efficient, and pragmatic corporate culture [26] - The company will adhere to its core marketing strategy, accelerate the layout of OTC and new retail channels, and expand sales through multiple measures to ensure stable performance growth [28][40] Group 3: Q&A Summaries Business and Strategy - The company's mission is to make thousands of Chinese children healthy and strong and become a leading enterprise in the field of children's health care and treatment. It focuses on the pharmaceutical main business, implements category extension and brand extension strategies, and expands the applicable age of Yikexin [34][41] - The company will actively manage its market value through measures such as standardized and transparent information disclosure, strengthening communication with investors, and implementing high - proportion dividends [34][35][42] - In 2025, the company will continue to improve the key technology platform for children's drugs, aiming for breakthroughs in children's respiratory and mental medications [35] Product - related - Yikexin has a market share of over 60%. The company will promote the "AD co - supplementation, 0 - 18 years old, one capsule per day" concept through various channels [34][37] - The company's product line is rich. In addition to Yikexin, products like Dain Tie, Dain Gai, and Xiao'er Ibuprofen Suppository have a broad market space and stable revenue growth [29] - The company's DHA products are designed for 0 - 12 - year - old children to promote eye and brain development, with different formulations to cover a wide range of customers [40] Market and Competition - The company will adhere to its core marketing strategy, strengthen brand promotion, and accelerate the layout of OTC and new retail channels to deal with the impact of competitors' centralized procurement [29][49] - The company's products are mainly sold through dealers, and it has established teams for hospitals, business, OTC, and new retail. The 2024 R & D investment was 97.1389 million yuan, accounting for 4.55% of revenue [47][48] Finance and Dividends - The company will maintain high - proportion dividends in the absence of major business investments and capital requirements, sharing development benefits with shareholders [38][39][47] Industry Outlook - The Chinese pharmaceutical industry is in a period of dual benefits from innovation and policy support, showing an expanding scale and rapid structural optimization. The children's pharmaceutical industry is moving towards precision and safety improvement [36]

Group 1: Company Performance and Financials - The company has maintained a high dividend payout, with the dividend amount for 2024 reaching 119% of the net profit attributable to the parent company [12] - In 2024, the company reported a significant decline in performance, with revenue and profit showing negative growth for the first time since 2019 [10][12] - R&D investment for 2024 was approximately 97.14 million, accounting for 4.55% of revenue [12] Group 2: Market Strategy and Product Development - The company focuses on children's health products, with a mission to become a leader in pediatric healthcare [10] - The market strategy emphasizes "expert authority recommendation, convenient purchasing channels, and professional category education" [11][12] - The company plans to expand the age range for its flagship product, Yikexin, from 0-6 years to 0-18 years, in line with new clinical guidelines [5][10] Group 3: Challenges and Responses - The decline in performance is attributed to a slowdown in the pharmaceutical industry, reduced market activity, and intensified competition among pharmacies [11][12] - The company is actively responding to market changes by increasing marketing efforts and enhancing online channel development [11][12] - The company aims to maintain stable growth by optimizing product structure and increasing R&D investment to introduce more competitive products [12] Group 4: Collaboration and Partnerships - The company collaborates with China Resources Sanjiu as the exclusive agent for its vitamin D products, enhancing market promotion and distribution [11] - Strategic partnerships with major distributors and e-commerce platforms are being strengthened to boost sales and market presence [12] Group 5: Future Outlook - The company is optimistic about the future of the pediatric pharmaceutical market, driven by increasing healthcare demands and supportive government policies [5][10] - Plans for 2025 include focusing on innovation in pediatric medications and expanding the product line to include more health supplements [10][12]

关于举行 2024 年度网上业绩说明会的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 证券代码：000915 证券简称：华特达因 公告编号：2025-014 山东华特达因健康股份有限公司 欢迎广大投资者积极参与本次业绩说明会。 特此公告 山东华特达因健康股份有限公司董事会 2025年4月9日 山东华特达因健康股份有限公司（以下简称"公司"）定于 2025 年 4 月 16 日（周三）15:00-16:00 在全景网举办 2024 年度业绩说明 会，本次业绩说明会将采用网络远程的方式举行，投资者可登录全景 网"投资者关系互动平台"（http://ir.p5w.net）参与本次业绩说明 会。 出席本次业绩说明会的人员有：总经理杨杰女士、独立董事杜宁 女士、财务总监谭立富先生、董事会秘书樊黎明先生。 为充分尊重投资者、提升交流的针对性，现就公司 2024 年度网 上业绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和 建议。投资者可于 2025 年 4 月 15 日(周二)15:00 前访问 http://ir.p5w.net/zj/或扫描下方二维码， ...

证券代码：000915 证券简称：华特达因 公告编号：2025-013 山东华特达因健康股份有限公司 第十一届董事会2025年第三次临时会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 山东华特达因健康股份有限公司第十一届董事会于 2025 年 4 月 3 日以电子邮件形式发出召开 2025 年第三次临时会议的通知，并于 2025 年 4 月 7 日以通讯方式召开会议。会议应参加董事 8 名，实际 参加董事 8 名。会议由公司董事长朱效平先生主持。会议符合有关法 律、法规、规章和《公司章程》的规定。 二、董事会会议审议情况 以 8 票同意 0 票弃权 0 票反对的表决结果，审议通过了"关于聘 任董事会秘书的议案"： 董事长朱效平提名樊黎明先生（简历见附件）为公司董事会秘书， 任期与第十一届董事会余任任期相同。 董事长朱效平先生不再代行董事会秘书职责。 董事会提名委员会 2025 年第二次会议对拟聘任的董事会秘书进 行了审核，认为：公司本次拟聘任董事会秘书的提名方式符合《公司 法》和《公司章程》的有关规定，拟聘任人员符合上市公 ...

截至公告披露日，李少东先生未持有公司股份。 股票代码：000915 股票简称：华特达因 公告编号：2025-012 山东华特达因健康股份有限公司 关于公司职工代表监事辞职暨补选的公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 山东华特达因健康股份有限公司（以下简称"公司"）监事会于 近日收到职工代表监事李少东先生的书面辞职报告。李少东先生因个 人原因辞去第十一届监事会职工代表监事职务。辞职后，李少东先生 仍在公司任职。 根据《公司章程》的规定，李少东先生的辞职报告在公司选举出 新的监事后生效。监事会对李少东先生在任职期间为公司做出的贡献 表示感谢。 2025 年 4 月 1 日，公司 2025 年度临时职工代表大会选举范智胜 先生（简历见附件）为第十一届监事会职工代表监事，任期与第十 一届监事会余任任期相同。 特此公告 山东华特达因健康股份有限公司监事会 截至目前范智胜先生与持有公司股份 5%以上的股东、公司其他 董事、监事、高级管理人员不存在关联关系；未曾受过中国证监会及 其他有关部门的处罚和证券交易所纪律处分；持有公司股份 5000 股； 不存在因涉 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 36.48 CNY over the next six months, while the current price is 28.64 CNY [1]. Core Insights - The company has a strong focus on pediatric medication, with steady progress in new product development. The main product, Yikexin, continues to be a cornerstone of performance, holding the top market share in its category. The expansion of its age applicability from 0-6 years to 0-18 years is expected to enhance its product portfolio [7][10]. - The company reported a total revenue of 2.134 billion CNY for 2024, a decrease of 14.1% year-on-year, and a net profit attributable to the parent company of 515.59 million CNY, down 11.9% year-on-year. The revenue decline is attributed to intensified competition, lower birth rates, and regional procurement policies affecting Vitamin AD [7][8]. - The company is increasing its R&D investment, with a research expense ratio of 4.8% in 2024, up 0.9 percentage points from 2023. It aims to enhance its product series through targeted pediatric drug development [7][8]. Financial Summary - Revenue projections for 2025-2027 are 2.344 billion CNY (+9.8%), 2.598 billion CNY (+10.8%), and 2.905 billion CNY (+11.8%) respectively. Net profit is expected to be 533.18 million CNY (+3.4%), 559.66 million CNY (+4.97%), and 633.55 million CNY (+13.2%) for the same years [2][9]. - The earnings per share (EPS) forecast for 2025-2027 is 2.28 CNY, 2.39 CNY, and 2.70 CNY respectively, with corresponding dynamic price-to-earnings (PE) ratios of 13, 12, and 11 [2][9]. - The company’s total market capitalization is approximately 6.932 billion CNY, with total assets of 4.931 billion CNY and a net asset value per share of 12.43 CNY [4][12]. Market Position and Competitive Landscape - The company is positioned as a leader in the pediatric medication market, with a focus on innovative product development and strategic marketing initiatives. The competitive landscape includes companies like Jianmin Group and Jichuan Pharmaceutical, which are also focused on pediatric medications [10][11].

华特达因(000915)：深耕儿童用药 新产品研发稳步 推进 事件：公司发布2024 年年报，全年实现营业总收入21.34 亿元，同比下降14.1%；归母净利润5.2 亿元， 同比下降11.9% 。营收下滑主要是由于竞争加剧、出生率不及预期、维生素AD部分区域进集采等因素 影响。从业务板块来看，公司主营医药业务，医药产业收入为21 亿元，占主营业务收入的98.2%。 明星产品伊可新筑业绩基石，《共识》推出有望打开新市场空间。伊可新为中国驰名商标，多年来一直 位居同类产品市场占有率第一。2024 年，根据中国品牌建设促进会的品牌价值评估，伊可新品牌的价 值达到37.14 亿元人民币。伊可新品牌荣获西鼎奖中国药品零售市场畅销品牌称号；小葫芦形象荣获西 湖奖最受欢迎IP 奖；伊可新维生素AD 滴剂荣获西湖奖最受药店欢迎的明星单品奖及米内网2024 中国 医药品牌榜零售终端获奖品牌；伊可新DHA 藻油+ARA 凝胶糖果荣获京东健康母婴营养行业峰会用户 喜爱单品奖。2024 年3 月，《中国儿童维生素A、维生素D临床应用专家共识》建议补充时长从3岁调整 为18 岁。 公司将伊可新的适用年龄由0-6 岁扩展到0-18 岁 ...

关于山东华特达因健康股份有限公司 非经营性资金占用及其他关联 资金往来的专项说明 致同会计师事务所（特殊普通合伙） 1 目 录 编制和对外披露汇总表，并确保其真实性、合法性及完整性是华特达因 管理层的责任。我们对汇总表所载资料与我们审计华特达因 2024 年度财务报 表时所复核的会计资料和经审计的财务报表的相关内容进行了核对，在所有 重大方面没有发现不一致。除了对华特达因实施于 2024 年度财务报表审计中 所执行的对关联方往来的相关审计程序外，我们并未对汇总表所载资料执行 额外的审计程序。为了更好地理解 2024 年度华特达因非经营性资金占用及其 他关联资金往来情况，汇总表应当与已审计的财务报表一并阅读。 1 本专项说明仅供华特达因披露年度报告时使用，不得用作任何其他用途。 关于山东华特达因健康股份有限公司非经营性资金占用及其他关 联资金往来的专项说明 1-2 山东华特达因健康股份有限公司2024年度非经营性资金占用及其 他关联资金往来情况汇总表 3 2 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传 ...

山东华特达因健康股份有限公司 二〇二四年度 内部控制审计报告 按照《企业内部控制审计指引》及中国注册会计师执业准则的相关要求， 我们审计了山东华特达因健康股份有限公司（以下简称"华特达因"或"公 司"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 致同会计师事务所（特殊普通合伙） 致同会计师事务所（特殊普通合伙） 中国北京 朝阳区建国门外大街 22 号 赛特广场 5 层 邮编 100004 电话 +86 10 8566 5588 传真 +86 10 8566 5120 www.grantthornton.cn 内部控制审计报告 致同审字（2025）第 371A002598 号 山东华特达因健康股份有限公司全体股东： 内部控制具有固有局限性，存在不能防止和发现错报的可能性。此外， 由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的 程度降低，根据内部控制审计结果推测未来内部控制的有效性具有一定风险。 中国注册会计师 刘健 中国注册会计师 杜娟 中国·北京 二〇二五年 三月十九日 四、财务报告内部控制审计意见 我们认为，华特达因于 2024 年 12 月 ...